ArticleOncology letters2019
Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Inflammation and RONS Dysregulation by Redox Enzymes as Mechanistic Links in HIV-1-Cancer Comorbidity.Pathogens (Basel, Switzerland) · 2026Review
- Development and validation of a multimodal radiomics-serum biomarker model for diagnosing solid pulmonary nodules via machine learning.Journal of thoracic disease · 2025Article
- The relationship between blood biomarkers and prognosis of pathologic stage IA pure-solid non-small cell lung cancer patients.Journal of thoracic disease · 2025Article
- The Diagnostic Significance of the Tumor Marker CYFRA 21-1 in Patients with Laryngeal Carcinoma.Materia socio-medica · 2025Article
- Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA.Journal of medical biochemistry · 2024Article
- Article
- Determination of Tumor Marker Screening for Lung Cancer Using ROC Curves.Disease markers · 2024Article
- Factors associated with overdiagnosis of benign pulmonary nodules as malignancy: a retrospective cohort study.BMC pulmonary medicine · 2023Article
- Serum lncRNA THRIL predicts benign and malignant pulmonary nodules and promotes the progression of pulmonary malignancies.BMC cancer · 2023Article
- Article
- [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- The Effect of Microwave Ablation Combined with Anti-PD-1 Monoclonal Antibody on T Cell Subsets and Long-Term Prognosis in Patients Suffering from Non-Small-Cell Lung Cancer.Computational and mathematical methods in medicine · 2022Article
- Clinical risk factors of carbohydrate antigen-125, cytokeratin fragment 19, and neuron-specific enolase in liver metastases from elderly lung cancer patients.Frontiers in genetics · 2022Article
- Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.Journal of clinical laboratory analysis · 2021Article
- Expression levels of SCCA and CYFRA 21-1 in serum of patients with laryngeal squamous cell carcinoma and their correlation with tumorigenesis and progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.Disease markers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression levels of thioredoxin (Trx), cytokeratin fragment 21-1 (CYFRA21-1) and serum squamous cell carcinoma antigen (SCCA) in patients with lung cancer and the diagnostic value of combined detection were investigated. Sixty-five patients with lung cancer in Weihai Municipal Hospital from January 2014 to June 2017 were retrospectively selected as the observation group, while 60 healthy subjects receiving physical examination were selected as the control group. The expression levels of serum Trx, CYFRA21-1 and SCCA were detected. The sensitivity and specificity of single detection and combined detection of these indexes were compared. Moreover, the diagnostic values of single detection and combined detection were analyzed using the receiver operating characteristic (ROC) curve. The levels of CYFRA21-1 and SCCA were the highest in squamous carcinoma (P<0.05). The level of Trx was the highest in small cell lung cancer compared with those in squamous carcinoma and adenocarcinoma (P<0.05). The levels of serum Trx, CYFRA21-1 and SCCA in lung cancer patients in clinical stage III-IV were obviously higher than those in patients in clinical stage I-II (P<0.001). The positive rate of Trx was the highest in small cell lung cancer, and the positive rates of CYFRA21-1 and SCCA were the highest in squamous carcinoma compared with other cancers (P<0.05). The area under the ROC curve of combined detection of the three indexes was the largest. The optimal cut-off value of combined detection of the three indexes in lung cancer was 9.952 with the sensitivity of 86.2% and specificity of 75.0%. The detection of serum Trx, CYFRA21-1 and SCCA is of great significance in the diagnosis, progression and pathological type of lung cancer, and combined detection can improve both specificity and sensitivity, which is more conducive to the positive rate of diagnosis of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.